24.12.2012 Views

Org. age Ohio . 711 - The Ohio State University

Org. age Ohio . 711 - The Ohio State University

Org. age Ohio . 711 - The Ohio State University

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

NIH Grants Awarded FY2005<br />

NIH, Principal Investigator<br />

Name Institute* Grant Number Project Title FY04 Award<br />

Au, Jessie L.-S. NCI R01CA93871-04 Chemoresistance in renal cell cancer $269,848<br />

NCI R01CA097067-04 FGF: a mechanism of acquired $245,219<br />

multidrug resistance<br />

Brueggemeier, NCI R01CA073698-07 Estrogen biotransformations and $277,300<br />

Robert W. breast cancer etiology<br />

Chan, Kenneth K NCI N01CM52205-01 Preclinical pharmacological study of $340,098<br />

antitumor and other agnts<br />

Chen, Ching-Shih NCI R01CA094829-05 Apoptosis regulation by lipid signals $199,125<br />

in prostate cancer<br />

NCI R21CA104776-02 Novel Celecoxib Derivatives as $134,550<br />

Chemopreventive Agents<br />

NCI R01CA112250-01 Targeting Akt and Bcl-2 in prostate $295,263<br />

cancer prevention<br />

Curley, Robert W. NCI R01CA049837-12 Analog studies of 4-HPR and its $297,510<br />

glucuronide<br />

Dalton, James T. NIDDK R01DK059800-06 Pharmacology of nonsteroidal $326,318<br />

androgen receptor ligands<br />

Elton, Terry NHLBI R01HL048848-13 Human angiotensin II receptor gene $224,250<br />

regulation<br />

Knoell, Daren L. NHLBI K08HL004462-04 Cytolytic attack against lung $126,942<br />

parenchyma in emphysema<br />

Lee, Robert J. NCI R01CA095673-03 Targeted liposomal doxorubicin $296,904<br />

delivery to leukemia<br />

Schmittgen, Thomas D. NCI R21CA107435-01 Micro RNA Expression and Cancer $134,550<br />

Werbovetz, Karl A. NIH R01AI061021-02 Simple, Selective Antimitotic $334,645<br />

Antiparasitic Agents<br />

Wientjes, M. Guillaume NCI R01CA100922-02 Enhanced Chemosensitivity of $272,138<br />

Pancreatic Cancer<br />

Wientjes, M. Guillaume NCI R21CA111770-01A1 Tumor priming to promote $192,855<br />

nanoparticle gene delivery<br />

Subtotal $3,967,515<br />

NIH, via subprojects and subcontracts:<br />

Name Institute* Grant Number Project Title FY04 Award<br />

Brueggemeier, NCI 5 P30 CA16058-27 Cancer Center Core grant $125,826<br />

Robert W.<br />

Carnes, Cynthia NHLB via R01HL65412-01 Oxictive stress and atrial fibrillation $75,000<br />

Cleveland<br />

Clinic<br />

Dalton, James T. NIH via KD065227-02 Novel irreversible SARMs for prostate $128,409<br />

Univ of cancer<br />

Tennessee<br />

McKay, Dennis B. NIH via 1R01DA13939 Analogues of methyllycaconitine $149,295<br />

<strong>Ohio</strong> as selective nicotinic <strong>age</strong>nts<br />

<strong>University</strong><br />

Tjarks, Werner NIH via R01CA098945 Molecular targeting of EGFR for the $39,383<br />

OSU treatment of gliomas<br />

subproject<br />

Subtotal $517,913<br />

Subtotal for NIH $4,485,428<br />

*National Institutes of Health (NIH); National Cancer Institute (NCI): National Institute of Diabetes & Digestive & Kidney<br />

Disease (NIDDK); National Heart Lung Blood Institute (NHLBI)<br />

55

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!